Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096831 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL5090914 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL5096829 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL2002304 | 0.84 | CHRM4 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL4827578 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL4827732 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL4827731 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL4827574 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL4827576 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRM4 | |
| SCHEMBL27497422 | 0.72 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | ABBOTT LABORATORIES (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | GRIN3A, GAP43, GRIN3B | CHRNB2 31/4885CHRNA4 19/4885CHRNB4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.